TOLNAFTATE 1%

N/A

Manufactured by Meijer Distribution Inc

724 FDA adverse event reports analyzed

Last updated: 2026-04-15

About TOLNAFTATE 1%

TOLNAFTATE 1% is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Meijer Distribution Inc. The most commonly reported adverse reactions for TOLNAFTATE 1% include DIARRHOEA, ARTHRALGIA, DYSPNOEA, DRUG INEFFECTIVE, PNEUMONIA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for TOLNAFTATE 1%.

Top Adverse Reactions

DIARRHOEA23 reports
ARTHRALGIA17 reports
DYSPNOEA16 reports
DRUG INEFFECTIVE14 reports
PNEUMONIA14 reports
BLOOD POTASSIUM INCREASED13 reports
GASTROINTESTINAL DISORDER13 reports
HEADACHE13 reports
RASH ERYTHEMATOUS13 reports
BRONCHOPULMONARY ASPERGILLOSIS12 reports
MUCORMYCOSIS12 reports
OFF LABEL USE12 reports
RENAL IMPAIRMENT12 reports
SKIN LESION12 reports
TOOTH DISORDER12 reports
DEPRESSION11 reports
FATIGUE11 reports
GRAFT VERSUS HOST DISEASE11 reports
NAUSEA11 reports
PYREXIA11 reports
RASH11 reports
BACK PAIN10 reports
VOMITING10 reports
ACUTE KIDNEY INJURY9 reports
BONE PAIN9 reports
NEUTROPENIA9 reports
ACUTE GRAFT VERSUS HOST DISEASE IN SKIN8 reports
C REACTIVE PROTEIN INCREASED8 reports
CHRONIC GRAFT VERSUS HOST DISEASE8 reports
DISEASE PROGRESSION8 reports
ENAMEL ANOMALY8 reports
FALL8 reports
OEDEMA PERIPHERAL8 reports
PRURITUS8 reports
SEPSIS8 reports
TOOTH HYPOPLASIA8 reports
WOUND8 reports
ACUTE GRAFT VERSUS HOST DISEASE IN INTESTINE7 reports
ANXIETY7 reports
CANCER PAIN7 reports
CONSTIPATION7 reports
DIZZINESS7 reports
ERYTHEMA7 reports
INSOMNIA7 reports
MUCOSAL INFLAMMATION7 reports
PAIN7 reports
PAIN IN EXTREMITY7 reports
CONDITION AGGRAVATED6 reports
DEATH6 reports
DRUG INTERACTION6 reports
FUNGAL INFECTION6 reports
HYPERSENSITIVITY6 reports
MEMORY IMPAIRMENT6 reports
PRODUCT USE IN UNAPPROVED INDICATION6 reports
RENAL FAILURE6 reports
SHOCK6 reports
URTICARIA6 reports
ABDOMINAL PAIN5 reports
ABDOMINAL PAIN UPPER5 reports
ALANINE AMINOTRANSFERASE INCREASED5 reports
CHEST DISCOMFORT5 reports
CHRONIC KIDNEY DISEASE5 reports
DIABETES MELLITUS5 reports
MALAISE5 reports
ORAL CANDIDIASIS5 reports
PLATELET COUNT DECREASED5 reports
POLLAKIURIA5 reports
SINUSITIS5 reports
WEIGHT DECREASED5 reports
WHITE BLOOD CELL COUNT INCREASED5 reports
ABDOMINAL DISCOMFORT4 reports
AMNESIA4 reports
ANAEMIA4 reports
ASTHENIA4 reports
BLOOD ALKALINE PHOSPHATASE INCREASED4 reports
BLOOD UREA INCREASED4 reports
BURNING SENSATION4 reports
CARPAL TUNNEL SYNDROME4 reports
CATARACT4 reports
COGNITIVE DISORDER4 reports
DRUG LEVEL INCREASED4 reports
DRY MOUTH4 reports
DYSPEPSIA4 reports
ERECTILE DYSFUNCTION4 reports
GAIT DISTURBANCE4 reports
HAEMOPTYSIS4 reports
HAEMORRHAGE4 reports
HEART RATE INCREASED4 reports
HYPOTENSION4 reports
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION4 reports
INTERVERTEBRAL DISC PROTRUSION4 reports
JOINT SWELLING4 reports
MUSCULOSKELETAL STIFFNESS4 reports
MYALGIA4 reports
NEUROPATHY PERIPHERAL4 reports
OEDEMA4 reports
PERIPHERAL SWELLING4 reports
PRODUCT DOSE OMISSION ISSUE4 reports
PRODUCTIVE COUGH4 reports
STEM CELL TRANSPLANT4 reports

Report Outcomes

Out of 281 classified reports for TOLNAFTATE 1%:

Serious 76.5%Non-Serious 23.5%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Female129 (50.6%)
Male125 (49.0%)
Unknown1 (0.4%)

Reports by Age

Age 6311 reports
Age 6210 reports
Age 578 reports
Age 97 reports
Age 727 reports
Age 756 reports
Age 515 reports
Age 555 reports
Age 605 reports
Age 615 reports
Age 675 reports
Age 695 reports
Age 464 reports
Age 534 reports
Age 684 reports
Age 734 reports
Age 784 reports
Age 183 reports
Age 403 reports
Age 413 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with TOLNAFTATE 1%?

This profile reflects 724 FDA FAERS reports that mention TOLNAFTATE 1%. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for TOLNAFTATE 1%?

Frequently reported terms in FAERS include DIARRHOEA, ARTHRALGIA, DYSPNOEA, DRUG INEFFECTIVE, PNEUMONIA, BLOOD POTASSIUM INCREASED. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures TOLNAFTATE 1%?

Labeling and FAERS entries often list Meijer Distribution Inc in connection with TOLNAFTATE 1%. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.